Practical Insights on Evolving Biomarkers for Precision Therapy in Lung Cancer

Practical Insights on Evolving Biomarkers for Precision Therapy in Lung Cancer (June 2020)

Thursday, June 25, 2020
Webinar -- 12:00 PM ET
http://www.clinicaloptions.com/Chicago2020LungBiomarkersJoin2

Agenda

Current Status of Biomarker Testing in Lung Cancer Edward S. Kim, MD, FACP

  • Guideline recommendations for testing in lung cancer: who should be tested and what should they be tested for?
  • Overview of testing: single-gene vs broad-based testing
  • Patient case discussion

New Clinically Available Biomarkers: Recognizing Meaningful Responses With Targeted Agents in NSCLC and Low-Frequency Alterations Leora Horn, MD, MSc, FRCPC

  • BRAF V600E
  • ROS1
  • NTRK
  • Patient case discussion

Therapeutic Targets Poised to Change Lung Cancer Care: Emerging and Near-Future Predictive Biomarkers Edward S. Kim, MD, FACP

  • RET
  • MET exon 14
  • KRAS G12C
  • EGFR exon 20
  • Patient case discussion

Evolving Understanding of Biomarkers of Response to Immune Checkpoint Inhibition in Lung Cancer Leora Horn, MD, MSc, FRCPC

  • PD-L1
  • TMB
  • Emerging biomarkers
  • Patient case discussion

Final Panel Discussion and Audience Question and Answer Session

Faculty

Program Director
Edward S. Kim, MD, FACP

Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Faculty
Leora Horn, MD, MSc, FRCPC

Ingram Associate Professor of Cancer Research 
Director
, Thoracic Oncology Research Program 
Assistant Vice Chairman for Faculty Development 
Vanderbilt Ingram Cancer Center 
Nashville, Tennessee

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung cancer.

Target Audience
This program is intended for physicians, pathologists, and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.